Shares of Alphatec Holdings continued sliding Monday, dropping 8.2% to $8.72 with no fresh catalyst, extending a brutal selloff that has carved more than a third off the stock since its May 5 earnings report. Q1 revenue of $192.1 million missed the $197.6 million Wall Street expected , and the stock initially plunged over 32% in after-hours trading . Today's move looks like continued post-earnings bleeding — broader indices are roughly flat — raising a pointed question: at what price does ATEC's fast-growing surgical business compensate for a stumbling imaging division?
The Revenue Miss Came From One Place: Equipment Installation Delays
EOS imaging revenue was $14 million, down $3 million year-over-year, as system deliveries fell below the prior year period, resulting in lower revenue recognition.
Management trimmed full-year total revenue guidance from roughly $891 million to $882 million, and the entire $9 million reduction sat on EOS; surgical guidance held at $805 million. For shareholders, a single underperforming segment triggered a market-cap loss exceeding $500 million — a disproportionate punishment that reveals how thin investor confidence had become.
The Core Spine Business Is Still Growing, but It's Not Enough to Calm Nerves
Surgical revenue hit $178 million, up 17% year-over-year , while case volume jumped 21% and new surgeon adoption rose 23% . Adjusted EBITDA guidance of roughly $134 million — about a 15% margin — was reaffirmed. Yet the stock still trades at $8.72, down from a 52-week high of $23.29, because investors need to see those volumes consistently convert to cash. GAAP net loss remained $33.9 million in Q1.
Wall Street Says Buy, but the Stock Keeps Falling
Post-earnings, Barclays, Wells Fargo, and J.P. Morgan reiterated Buy-equivalent ratings with targets ranging from $14 to $24, while TD Cowen slashed its target to $11 from $20.
The average analyst price target sits near $18.91 — more than double the current price. That gaping disconnect suggests either Wall Street is lagging reality or the market is over-discounting a temporary installation hiccup.
One Insider Bought the Dip; Others Have Been Selling
Director Keith Valentine purchased 135,000 shares in May at roughly $7.00–$7.55 , a meaningful personal bet. But insiders collectively logged 37 trades in the prior six months — all sales, zero purchases. Until Q2 results on July 27 prove EOS delays are temporary and surgical momentum holds, the stock is in show-me territory with no floor in sight.